Alkermes vs Amneal Pharmaceuticals
ALKS and AMRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALKS and AMRX compare
Alkermes is the larger company, worth 1.2 times as much as Amneal Pharmaceuticals ($8.0B against $6.9B).
On earnings, Amneal Pharmaceuticals is cheaper: it trades at 51.7× trailing earnings, against 126× for Alkermes.
Alkermes grew revenue faster over the last twelve months (10.8% versus 8.9% for Amneal Pharmaceuticals).
Amneal Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 4.2% compared with 4.0% at Alkermes.
Amneal Pharmaceuticals scores higher on the StockData Score (12 against 5 for Alkermes), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALKS | AMRX |
|---|---|---|
| Size and price | ||
| Market cap | $8.0B | $6.9B |
| Share price | $47.89 | $21.71 |
| Change, 1 year | 46.7% | 89.1% |
| Change, 5 years | 106% | 370% |
| Beta (5Y) | 0.41 | 1.07 |
| Employees | 2,050 | 8,500 |
| StockData Score | ||
| Total score | 5 | 12 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 5 (better) |
| Performance score | 2 | 5 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 126× | 51.7× (better) |
| P/S | 4.8× | 2.2× (better) |
| P/B | 4.4× (better) | 13.1× |
| EV/EBITDA | 49.6× | 20.3× (better) |
| P/FCF | 36.2× (better) | 78.6× |
| FCF yield | 2.8% (better) | 1.3% |
| Fair value | $15.32 | $13.08 |
| Margin of safety | −213% | −66.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 10.8% (better) | 8.9% |
| Revenue growth, 5Y average | 7.3% | 8.7% (better) |
| Net income growth (TTM) | −81.0% | 2159% (better) |
| EPS growth (TTM) | −81.7% | 2000% (better) |
| EPS growth, 5Y average | – | −18.5% |
| Profitability | ||
| Gross margin | 84.6% (better) | 40.2% |
| Operating margin | 7.0% | 15.0% (better) |
| Net margin | 4.0% | 4.2% (better) |
| FCF margin | 13.3% (better) | 2.8% |
| Return on equity | 3.9% | 63.2% (better) |
| Return on invested capital | 4.9% | 16.3% (better) |
| Financial health | ||
| Debt / equity | 0.83 (better) | 5.53 |
| Net debt / EBITDA | 4.73 (better) | 5.81 |
| Interest coverage | 2.0× | – |
| Current ratio | 2.30 (better) | 1.87 |
| Altman Z-score | 2.31 (better) | 1.89 |
| Piotroski F-score | 7 | 7 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 106% | 52.7% |
| Held by insiders | 1.6% | 60.7% |
| Insider net buying, 12 months | −$10.1M | −$7.7M (better) |
| Short interest, % of float | 11.9% | 9.1% |
Go deeper
- ALKS stock overview
- ALKS income statement
- ALKS valuation and score
- AMRX stock overview
- AMRX income statement
- AMRX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.